TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

Phase 1 Completed 13 enrolled Tibotec Pharmaceuticals, Ireland

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase I, open-label, single-sequence drug-drug interaction trial in patients on stable methadone maintenance therapy is to investigate the potential interaction between TMC278 25 mg daily and methadone, at steady-state.

Timeline

Start: 2008-10
Primary completion: 2009-06
Completion: 2009-06

Publications

Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. J Clin Pharmacol. 2014 Feb;54(2):133-40. doi: 10.1002/jcph.222. Epub 2013 Nov 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rilpivirine	Small molecule	25 mg	Oral

TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

Summary

Timeline

Publications

Drugs

Indications